On the morning of November 16, during the “2017 China (Lianyungang) International Medical Technology Conference”, Ma Qiulin, deputy governor of Jiangsu Province, and Sun Xianze, deputy head of the State Food and Drug Administration and director of the Chinese Pharmaceutical Association, inspected Hansoh Pharma, accompanied by Mo Zongtong, director of the Provincial Food and Drug Administration, Yang Xingshi, Lianyungang Municipal Party Committee Secretary, Cao Weidong, member of the Standing Committee of Municipal Party Committee and secretary of Development Zone Party Working Committee Secretary, Wang Dongsheng, secretary-general of Municipal Party Committee, and Vice Mayor Xu Jiabao, as well as relevant department heads. Ms. Zhong Huijuan, Chairman of the Group, introduced the development of Hansoh Pharmaceutical to the visiting leaders.

Zhong Huijuan, Chairman of the Group, presents the technological innovation of Hansoh to the visiting leaders

The visiting leaders visited the Group’s exhibition hall, Lianyungang research institute and the pharmaceutical industrial park, and gained a key understanding of the technological innovation of enterprises, the progress of major projects, and advanced equipment and facilities. After hearing the presentation of Hansoh Pharma’s frequent breakthroughs in medical technology, which allow domestic patients to afford international high-end drugs, the leaders nodded in agreement and praised the social contribution Hansoh has made to the progress of building a healthy society, while expressing their expectation of the launch of new drugs in oncology and endocrine therapeutic areas by Hansoh.

In recent years, the Group has made great efforts in marketing and innovation to build on quality excellence: with market-oriented and market-leading innovation, a number of first-to-market generic drugs have become hot products once launched, such as Xinwei (Imatinib Mesylate Tablets), a drug for leukemia treatment. Before the drug was included into the national medical insurance program, leukemia patients and their families phoned in one after another to express their support, facilitating the successful integration of Xinwei into the national program in February this year.

At present, the Group has completed the transformation and upgrading from “imitation and innovation” to independent innovation. In addition to the nearly 20 Category 1 national innovation drugs which are in various clinical stages, multi-center clinical trials are also being done globally. In the future, based on the internationalization of pharmaceutical manufacturing, Hansoh will accelerate the internationalization of innovation drugs to expand the benefit to global patients.